05 Nov 09 Acceleron Pharma Initiates First-in-Human Study Of ACE-041, A Novel Angiogenesis Inhibitor, In Patients With Advanced Cancer

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.

Related Posts:

Clavis Pharma Initiates Phase II Clinical Study Of Intravenous CP-4126 In Patients With Advanced Pancreatic Cancer Clavis Pharma ASA (OSE: CLAVIS) announced initiation of the first...
Polymorphism In Endostatin, An Angiogenesis Inhibitor, And Prostate Cancer Risk And Survival: A Prospective Study UroToday.com - Angiogenesis is the process of new blood vessel...
Onyx Pharmaceuticals Initiates Phase 1 Study Of Oral Proteasome Inhibitor In Advanced Solid Tumors Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced the initiation of a...
GTx Initiates Phase I Clinical Trial For GTx-758, An Oral Luteinizing Hormone Inhibitor For Advanced Prostate Cancer GTx, Inc. (NASDAQ: GTXI) announced today that it has initiated...
Ipsen Initiates An Advanced Endometrial Cancer Program With BN83495, Its First-in-Class Steroid Sulfatase Inhibitor First Patient Dosed In Phase II Ipsen (Paris:IPN) announced the initiation of an international, multi-center, controlled,...
Presidio Pharmaceuticals, Inc. Initiates First-in-Human Clinical Trial Of PPI-461, An Investigational NS5A Inhibitor For HCV Presidio Pharmaceuticals, Inc. announced that the UK Medicines and Healthcare...